These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 8630686

  • 1. High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas.
    Güllü I, Yalçin S, Tekuzman G, Barişta I, Alkiş N, Celik I, Zengin N, Güler N, Kars A, Baltali E.
    Cancer Invest; 1996; 14(3):239-42. PubMed ID: 8630686
    [Abstract] [Full Text] [Related]

  • 2. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
    Coriat R, Mir O, Camps S, Ropert S, Billemont B, Leconte M, Larousserie F, Anract P, Alexandre J, Goldwasser F.
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140
    [Abstract] [Full Text] [Related]

  • 3. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
    Skubitz KM, Hamdan H, Thompson RC.
    Cancer; 1993 Nov 15; 72(10):2963-9. PubMed ID: 8221562
    [Abstract] [Full Text] [Related]

  • 4. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
    Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH.
    J Clin Oncol; 1989 Sep 15; 7(9):1208-16. PubMed ID: 2504890
    [Abstract] [Full Text] [Related]

  • 5. A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
    Cantwell BM, Carmichael J, Ghani S, Harris AL.
    Cancer Chemother Pharmacol; 1988 Sep 15; 21(1):49-52. PubMed ID: 3124971
    [Abstract] [Full Text] [Related]

  • 6. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
    Antman KH, Elias A, Ryan L.
    Semin Oncol; 1990 Apr 15; 17(2 Suppl 4):68-73. PubMed ID: 2110386
    [Abstract] [Full Text] [Related]

  • 7. Dana-Farber Cancer Institute studies in advanced sarcoma.
    Antman KH, Elias A.
    Semin Oncol; 1990 Feb 15; 17(1 Suppl 2):7-15. PubMed ID: 2106162
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Treatment of advanced refractory sarcomas with ifosfamide and etoposide combination chemotherapy.
    Yalçin S, Güllü I, Barişta I, Tekuzman G, Ozişik Y, Celik I, Kars A.
    Cancer Invest; 1998 Feb 15; 16(5):297-302. PubMed ID: 9627675
    [Abstract] [Full Text] [Related]

  • 10. Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study.
    Elias AD, Antman KH.
    Cancer Treat Rep; 1986 Jul 15; 70(7):827-33. PubMed ID: 3087617
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
    Graziano SL, Herndon JE, Richards F, DiFino S, Modeas C, Duggan DB, Green MR.
    Cancer; 1993 Jul 01; 72(1):62-8. PubMed ID: 8389667
    [Abstract] [Full Text] [Related]

  • 18. Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma.
    Wiklund TA, Blomqvist CP, Virolainen M, Elomaa I.
    Cancer Chemother Pharmacol; 1992 Jul 01; 30(2):100-4. PubMed ID: 1600589
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of ifosfamide combined with Mesna uroprotection in advanced non-small-cell lung carcinoma and other solid tumors.
    Nobile MT, Rosso R, Brema F, Cinquegrana A, Santi L.
    Tumori; 1984 Oct 31; 70(5):433-7. PubMed ID: 6438851
    [Abstract] [Full Text] [Related]

  • 20. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
    Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS.
    J Clin Oncol; 1997 Jun 31; 15(6):2378-84. PubMed ID: 9196153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.